Copernicus SOCT receives FDA clearance

Article

Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.

Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.

The Copernicus is designed for in vivo imaging and measurement of the retina by using spectral tomography to rapidly create high-resolution images of retinal structures. These detailed three-dimensional images enhance a physician's ability to diagnose and monitor retinal disease and perform pre- and post procedural assessments of patients.

The SOCT was the first commercially available device on the world market.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
© 2024 MJH Life Sciences

All rights reserved.